je.st
news
Tag: merck
Merck Animal Health Shares Progress On Zilmax And The Five-Step Plan For Responsible Beef
2013-12-13 16:26:53| Beef
During the last 90 days, Merck Animal Health, with the input and oversight of its Advisory Board, has worked to implement its Five-Step Plan to Ensuring Responsible Beef and has made considerable progress. The findings that come as a result of the plan will add to the significant amount of data that already exists for Zilmax® (zilpaterol hydrochloride), including numerous animal safety and well-being trials. Zilmax is a feed supplement approved by the FDA and other regulatory authorities. read more
Tags: health
plan
responsible
progress
Merck Statement on FDA Advisory Committee for GRASTEK (Timothy Grass Pollen Allergen Extract), Mercks Investigational Sublingual Allergy Immunotherapy Tablet
2013-12-13 01:17:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued the following statement after the conclusion of the Allergenic Products Advisory Committee of the U.S. Food and Drug Administration (FDA) meeting to discuss GRASTEK (Timothy grass pollen allergen extract). Language: English Contact: MerckMedia:Pamela Eisele, 908-423-5042orRobert Consalvo, 908-423-6595orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: statement
committee
advisory
grass
Merck Advances Development Program for Investigational Alzheimers Disease Therapy, MK-8931
2013-12-10 13:00:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. Data Monitoring Committee recommends continuation of Phase II/III EPOCH study in mild to moderate disease patients Merck also plans to initiate dosing in Phase III study of prodromal disease patients WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on the development program for MK-8931, a novel investigational oral -amyloid precursor protein site-cleaving enzyme (BACE) inhibitor. Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639Justine OMalley, 908-423-2021orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: development
program
disease
therapy
Germany's Merck Bets On Chips
2013-12-06 17:18:33| Electronics - Topix.net
In a bid to broaden its offering to the electronics industry, the German drug and chemical maker Merck KGaA has agreed to purchase AZ Electronic Materials for $2.6 billion.
Tags: chips
bets
merck
germanys
Merck KGaA CEO says has firepower for more deals
2013-12-06 12:13:44| Biotech - Topix.net
"These acquisitions could take place in all of the businesses that we have," Chief Executive Karl-Ludwig Kley told Journalists at a press conference on Thursday.
Sites : [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] next »